Neurofibromas – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Neurofibromas are benign nerve sheath tumors composed of differentiated neoplastic Schwann cells and a mixture of nonneoplastic components. These tumors can present as nodular and well-demarcated or diffuse growths. Intraneural neurofibromas typically grow along the nerve confined within its epineurium. The main cellular constituents of neurofibromas are neoplastic Schwann cells, characterized by small, curved, or elongated nuclei, along with fibroblasts embedded within a myxoid/collagenic matrix in varying proportions. While neurofibromas may exhibit focal resemblance to Antoni B pattern, they lack Antoni A pattern and hyalinized blood vessels, distinguishing them from schwannomas. The Schwann cell component in neurofibromas shows expression of S100 and SOX10 proteins. Both sporadic and syndromic neurofibromas are associated with a deletion in the NF1 gene. Sporadic cases only involve the lesional cells carrying the NF1 mutation, while syndromic cases result from a germline mutation in NF1, which encodes the tumor suppressor protein neurofibromin, located on chromosome 17q11.2. Diagnosing solitary superficial neurofibromas involves physical examination or excisional biopsy with microscopic examination. For larger lesions, additional imaging with CT/MRI is required to assess the extent of involvement and plan for surgical excision. Complete surgical excision is the preferred treatment for most cases, with an exceedingly low rate of local recurrence. Currently, there are no alternative therapies available for cutaneous neurofibromas. In rare instances in which complete surgical excision is not feasible for diffuse or plexiform neurofibromas, partial resection may be performed for cosmetic or symptomatic relief. All types of neurofibromas are benign, and the risk of malignant transformation is exceedingly low. However, around 10% of patients with NF1 may experience malignant transformation, emphasizing the importance of considering NF1 for any patient presenting with a plexiform neurofibroma. Plexiform neurofibromas are the most common precursor to malignant peripheral nerve sheath tumors (MPNSTs). Complications related to localized neurofibromas are typically mild and primarily associated with surgical excision, including pain, scarring, bleeding, and local infection. In plexiform lesions, complications arise from the inherent risks of surgery and the possibility of incomplete lesion removal. Patients with NF1 who have persistent lesions are at an increased risk of malignant transformation to malignant peripheral nerve sheath tumors (MPNSTs).

·       Neurofibromatosis type 1 (NF1) accounts for approximately 96% of all neurofibromatosis cases, with a prevalence of 1 in 3000 births. It occurs equally between genders and races, and 50% of cases are associated with spontaneous mutations, while the other half has an inherited mutation. NF1 exhibits a 100% penetrance with variable expressivity.

·       Neurofibromatosis type 2 (NF2) makes up around 3% of cases, with a prevalence between 1 in 33,000 births and 1 in 87,410. NF2 does not show gender or race predilection and presents variable manifestations among different families.

Thelansis’s “Neurofibromas Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neurofibromas treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Neurofibromas across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Neurofibromas Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Neurofibromas – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more